Akebia Therapeutics Inc.
0.0 %
38.1 %
Yet to be announced
Company Overview
Akebia Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for patients with kidney disease. Their primary product is Auryxia® (ferric citrate), an oral therapy for the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis.
Revenue Sources
Based on review of SEC filings and company reports, Akebia Therapeutics' revenue primarily comes from the sale of Auryxia, a pharmaceutical product used to treat kidney disease patients. The company's business model and revenue sources are halal compliant as they involve the development and sale of legitimate medical treatments.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $37.43m | $49.93m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $43.65m | $52.37m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $32.61m | $48.06m | - | $517,000 | 0.00% | 1.08% |
| Dec. 31, 2023 | $56.2m | $54.82m | - | - | 0.00% | 0.00% |
Looking at the last four quarters of financial data, interest expense has been minimal or non-existent for most quarters, with only one quarter showing an interest expense of $517,000 which was not material relative to total expenses. The company has maintained low interest expenses relative to their total expenses, falling well below concerning thresholds.
Operational Ethics
Based on review of company documents and public information, there is no evidence of significant ongoing associations with entities involved in human rights violations. The company's operations are primarily focused in the United States and partner countries with no concerning ties identified.
Login to join the discussion